Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Lenvatinib Polymorph Forms in Healthy Volunteers
NCT02723630Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2013
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenvatinib in thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and 1 more (6 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Zero Time to Time of Last Quantifiable Concentration, Area Under the Concentration-Time Curve From Zero Time Extrapolated to Infinite Time and 1 more. Started Jul 2013; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)endometrial carcinoma
Beyond the preview
Go deeper on NCT02723630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723630.